Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

April 30, 2008

Conditions
Parkinson's DiseasePsychotic Disorders
Interventions
DRUG

Melperone HCl

20 mg/day. Strength of melperone syrup is 5 mg/mL

DRUG

Melperone HCl

40 mg/day. Strength of melperone syrup is 5 mg/mL

DRUG

Melperone HCl

60 mg/day. Strength of melperone syrup is 5 mg/mL

DRUG

Placebo

Syrup formulation

Trial Locations (21)

28204

Neurology Consultants of the Carolinas, Charlotte

33606

University of South Florida, Tampa

34205

Bradenton Research Center, Inc, Bradenton

45267

University of Cincinnati Medical Center, Cincinnati

48025

Quest Research Institute, Bingham Farms

55427

Struthers Parkinson's Center, Park Nicollet Health Services, Golden Valley

63110

Washington University School of Medicine, St Louis

66013

Fondazione Universita di Chieti C.E.S.I. Centro Studi sull'Invecchiamento, Chieti Scalo

66160

The University of Kansas Medical Center, Kansas City

78217

Neurology Associates, San Antonio

85741

Northwest Neurospecialists, PLLC, Tucson

98124

"IRCCS Centro Neurolesi Bonino Pulejo", Messina

560017

Department of Neurology, Manipal Hospital, Bangalore

560054

M. S. Ramasah Memorial Hospital, Bangalore

530 002

Department of Neurology, Rajendra Prasad Ward, King George Hospital, Visakhapatnam, Visakhapatnam

590 010

KLE Hospital, Belgaum, Belagavi

575 001

Kasturra Medical College, Hospital, Attavar, Mangalore

695 011

SCTIMST, Trivandrum

400 026

Jaslok Hospital and Research Center, Mumbai

600 006

Apollo Hospitals Educational and Research Foundation, Chennai

00163

U.O. Neurologia IRCCS San Raffaele Pisana, Rome

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Lundbeck LLC

INDUSTRY